Fig. 5
![Fig. 5](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs40425-018-0315-0/MediaObjects/40425_2018_315_Fig5_HTML.gif)
Computed tomography (CT) scans at baseline, 6-week, and subsequent assessment for two separate mRCC patients treated with PD-1/PD-L1 ICB. The first patient (upper panels) had stable disease (SD) on 6-week scan with a 34% decrease in NLR from baseline and subsequently displayed partial response (PR) on next assessment. The second patient (lower panels) had SD on 6-week scan with a 113% increase in NLR from baseline and subsequently displayed progressive disease (PD) on next assessment. Arrows (white) show change in selected area of disease burden